Evidence map›Paper›PMID 38680018›Full record

Trial reportBrain and behavior2024

Total intracranial hemorrhage volume measurement summating all compartments best in traumatic and nontraumatic intracranial bleeding.

MacKenzie Horn, Ankur Banerjee, Linda Kasickova, Ondrej Volny, Hyun Seok Choi, Federica Letteri, Tomoyuki Ohara, Koji Tanaka, Stuart Connolly, Per Ladenvall and 6 more

Abstract readRandomized Controlled Trial
In one paragraph

Trial report in Brain and behavior, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Trial
  2. A Standardized Anatomical Classification of Intracranial Hemorrhage.Cerebrovascular diseases (Basel, Switzerland) · 2026
    Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

MacKenzie HornDepartment of Clinical Neurosciences, University of Calgary, Calgary, Canada.
Ankur BanerjeeDepartment of Medicine, Division of Neurology, University of Alberta, Edmonton, Canada.ORCID 0000-0002-5185-4749
Linda KasickovaFaculty of Medicine, Masaryk University, Brno, Czech Republic.
Ondrej VolnyDepartment of Neurology, University Hospital Ostrava, Ostrava, Czech Republic.
Hyun Seok ChoiDepartment of Radiology, Seoul Medical Center, Seoul, South Korea.
Federica LetteriUnit of Neurology, San Jacopo Hospital, Pistoia, Italy.
Tomoyuki OharaDepartment of Neurology, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Koji TanakaDepartment of Clinical Neurosciences, University of Calgary, Calgary, Canada.
Stuart ConnollyDepartment of Medicine, McMaster University, Hamilton, Ontario, Canada.
Per LadenvallBiopharmaceuticals R&D, AstraZeneca, Mölndal, Sweden.
Mark CrowtherDepartment of Medicine, McMaster University, Hamilton, Ontario, Canada.
Jan Beyer-WestendorfUniversity Hospital Carl Gustav Carus Dresden, Dresden, Germany.
Ashkan ShoamaneshDepartment of Medicine, McMaster University, Hamilton, Ontario, Canada.
Andrew M DemchukDepartment of Clinical Neurosciences, University of Calgary, Calgary, Canada.
Abdulaziz S Al SultanDepartment of Medicine, Division of Neurology, Royal Columbian Hospital, New Westminster, Canada.ORCID 0000-0003-2849-5386
ANNEXa‐4 Investigators

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

background and purposeThe ANNEXA-4 trial measured hemostatic efficacy of andexanet alfa in patients with major bleeding taking factor Xa inhibitors. A proportion of this was traumatic and nontraumatic intracranial bleeding. Different measurements were applied in the trial including volumetrics to assess for intracranial bleeding depending on the compartment involved. We aimed to determine the most reliable way to measure intracranial hemorrhage (ICrH) volume by comparing individual brain compartment and total ICrH volume.

methodsThirty patients were randomly selected from the ANNEXA-4 database to assess measurement of ICrH volume by compartment and in total. Total and compartmental hemorrhage volumes were measured by five readers using Quantomo software. Each reader measured baseline hemorrhage volumes twice separated by 1 week. Twenty-eight different ANNEXA-4 subjects were also randomly selected to assess intra-rater reliability of total ICrH volume measurement change at baseline and 12-h follow up, performed by three readers twice to assess hemostatic efficacy categories used in ANNEXA-4.

resultsCompartmental minimal detectable change percentages (MDC%) ranged between 9.72 and 224.13, with the greatest measurement error occurring in patients with a subdural hemorrhage. Total ICrH volume measurements had the lowest MDC%, which ranged between 6.57 and 33.52 depending on the reader.

conclusionMeasurement of total ICrH volumes is more accurate than volume by compartment with less measurement error. Determination of hemostatic efficacy was consistent across readers, and within the same reader, as well as when compared to consensus read. Volumetric analysis of intracranial hemostatic efficacy is feasible and reliable when using total ICrH volumes.

Indexed as

Factor XaIntracranial HemorrhagesAdultAgedBrainFactor Xa InhibitorsFemaleHumansMaleMiddle AgedRecombinant ProteinsReproducibility of ResultsFactor XaFactor Xa InhibitorsPRT064445Recombinant Proteinsneuroimagingneurologyneurosciencestroke

Identifiers

PMID38680018
PMCPMC11056697

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.